CYP19A1 and Gynecomastia: The use of nonaromatizable androgens such as dihydrotestosterone would be preferable to testosterone, which may theoretically worsen gynecomastia in PAIS and would need to be used cautiously, perhaps in combination with aromatase antagonists.